Secuenciación en cáncer de mama avanzado HER2+ - page 43

EMILIA: Progression-Free Survival
by Independent Review in 2
nd
line
496
404
310
176
129
73
53
35
25
14
9
8
5
1
0
0
495
419
341
236
183
130
101
72
54
44
30
18
9
3
1
0
Cap + Lap
T-DM1
No. at risk by independent review:
Median
(months)
No. of
events
Cap + Lap
6.4
304
T-DM1
9.6
265
Stratified HR=0.650 (95% CI, 0.55, 0.77)
P
<0.0001
0.0
0.2
0.4
0.6
0.8
1.0
0
2
4
6
8
10
12 14
16
18
20
22
24
26
28
30
Proportion progression-free
Time (months)
Unstratified HR=0.66 (
P
<0.0001).
Verma S, NEJM 2012
1...,33,34,35,36,37,38,39,40,41,42 44,45,46,47,48,49,50,51,52,53,...60
Powered by FlippingBook